Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data - Wikidata - wikimedia - TriplyDB

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

http://www.wikidata.org/entity/Q30936712

about

Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review Romidepsin targets multiple survival signaling pathways in malignant T cells Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.The discovery and development of romidepsin for the treatment of T-cell lymphoma.Targeting histone deacetylases in T-cell lymphoma.Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Overcoming resistance to DNA targeted agents by epigenetic activation of Schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

P2860

Q26781365-807EF4B7-4D58-40EA-A95B-82AF15F7CEF3 Q28075343-DBDFF2DA-6A2B-4762-B84C-D9A92A739CB7 Q36254237-545C0C39-4643-4EF4-95FB-CAF17A03CC6D Q37609238-41816858-94C7-4D72-803E-F7BFD7D6F27C Q38379898-1E642585-70F9-4764-AEE5-0D09CD492825 Q38602496-54F08174-6F82-4FEE-B45B-34F6EEF0AD77 Q38713744-86E88992-1F43-44EC-87B3-1A5BC3E77A6A Q38998630-8D6B5933-04AC-4BF8-AFA2-EA67C6970C24 Q42009840-CFE4D5AE-FBAA-4814-AAE1-99D8F2422ED7 Q47567993-29C69D54-2907-4CCC-BA9D-95A9DF415500 Q49390599-77F832AA-7A98-4E40-8077-271AF2BA6DE6 Q57270689-F57A9995-EB61-4C45-A6A6-844E1291FB37

P2860

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

http://www.wikidata.org/entity/Q30936712

description

2015 nî lūn-bûn

@nan

2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Romidepsin in peripheral and c ...... clinical and correlative data

@ast

Romidepsin in peripheral and c ...... clinical and correlative data

@en

type

label

Romidepsin in peripheral and c ...... clinical and correlative data

@ast

Romidepsin in peripheral and c ...... clinical and correlative data

@en

prefLabel

Romidepsin in peripheral and c ...... clinical and correlative data

@ast

Romidepsin in peripheral and c ...... clinical and correlative data

@en

P1433

Q30936712-5C9ED662-903D-45B7-A4E9-A10EF0D5BDA9

P1476

Q30936712-CCAE78BC-F982-40F6-92DC-5AB02EB9A8DB

P2093

Q30936712-1DBB95FE-8FE7-4338-A02A-AE69A554E106

Q30936712-23972392-9CA6-4984-82EE-C4A7F0DD2E3A

Q30936712-2B636FC1-D04D-4C22-81A6-D749188F4807

Q30936712-3629175C-10ED-4E63-9FF4-33FA9A8ED74A

Q30936712-3A14DECD-35C8-4696-B247-BBF09B090F01

Q30936712-4C3EF1F0-6487-4F3C-9022-78B8B7EC7E89

Q30936712-4CA25C24-6A56-4D60-9C54-83281188DE9A

Q30936712-4FA93EFE-93CB-4079-AC95-26AE45C02593

Q30936712-565DE1C7-BDFD-4730-971A-9A84CE87EDE2

Q30936712-66A4624A-A1FC-4AEF-93B9-EE6B6CAA0748

P2860

Q30936712-008EAEB5-2B75-4376-BA8F-64EFFB292E24

Q30936712-022C7467-6AFD-4205-B0FF-113A8BAE1B62

Q30936712-03C4E235-BB19-4CD1-9005-67DD5141280A

Q30936712-057ECFBC-173B-4E68-B40D-E8AC718C87E2

Q30936712-0630973D-8D12-4EF4-99BF-681424DF0A30

Q30936712-076DE778-9097-4088-B6B6-17AAD7502212

Q30936712-0CE4C509-365F-42E5-9989-C8A4B819794E

Q30936712-0FAF88E3-84E2-461B-9AD4-781A154BA082

Q30936712-114CCDD5-9E3B-45E9-9C90-A7A2E1DC7842

Q30936712-14458D34-8F5A-4C50-82AD-D00F23CD5D24

P304

Q30936712-61840717-E467-4A34-BB77-B9D06A1D01DA

P31

Q30936712-E0A7A1A6-F7D0-4CA6-9465-D01D6DD6EC57

P356

Q30936712-C2BF6FD3-6CFD-4BEE-8115-BE7D6F09FC34

P407

Q30936712-EE2636CF-B9C3-4336-A66E-D7931E262186

P433

Q30936712-7FD5C460-520B-4515-9078-D233E5F7C389

P478

Q30936712-8940A10F-480C-4EEB-9C24-655AA7A7CB6C

P50

Q30936712-0BBA54B0-C5BB-4242-84AC-00A8A8A08A4F

Q30936712-DA971032-B16B-434A-86D4-4652F6618A7E

P577

Q30936712-57FAE4AD-2E18-4199-98C1-99726132AD67

P5875

Q30936712-98EFF831-D009-4D87-BAA7-6A8A20CA114D

P698

Q30936712-F7E4EE5F-D4C0-40DB-8CDB-6A3E10F2B6CB

P932

Q30936712-984BB2B2-F12B-4E3C-8629-6E8E65340D70

P356

P1433

British Journal of Haematology

P1476

Romidepsin in peripheral and c ...... clinical and correlative data

@en

P2093

Alexander Ling

http://www.w3.org/2001/XMLSchema#string

Caryn Steakley

http://www.w3.org/2001/XMLSchema#string

David J Liewehr

http://www.w3.org/2001/XMLSchema#string

David Joske

http://www.w3.org/2001/XMLSchema#string

Douglas Rosing

http://www.w3.org/2001/XMLSchema#string

Edward W Cowen

http://www.w3.org/2001/XMLSchema#string

Elaine S Jaffe

http://www.w3.org/2001/XMLSchema#string

H Miles Prince

http://www.w3.org/2001/XMLSchema#string

Jasmine Zain

http://www.w3.org/2001/XMLSchema#string

Jean Nichols

http://www.w3.org/2001/XMLSchema#string

P2860

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

Clinical and molecular responses in lung cancer patients receiving Romidepsin.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.

P304

96-109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13400

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275216143

http://www.w3.org/2001/XMLSchema#string

P698

25891346

http://www.w3.org/2001/XMLSchema#string

P932

4675455

http://www.w3.org/2001/XMLSchema#string